Comparing of XBiotech Inc. (XBIT) and Hoth Therapeutics Inc. (NASDAQ:HOTH)

Since XBiotech Inc. (NASDAQ:XBIT) and Hoth Therapeutics Inc. (NASDAQ:HOTH) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation of both companies.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
XBiotech Inc. N/A 0.00 21.14M -0.65 0.00
Hoth Therapeutics Inc. N/A 0.00 2.50M -0.24 0.00

Table 1 highlights XBiotech Inc. and Hoth Therapeutics Inc.’s gross revenue, earnings per share (EPS) and valuation.


Table 2 shows us XBiotech Inc. and Hoth Therapeutics Inc.’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
XBiotech Inc. 0.00% -41.4% -39.5%
Hoth Therapeutics Inc. 0.00% 0% 0%

Institutional & Insider Ownership

Roughly 13.2% of XBiotech Inc. shares are owned by institutional investors while 0% of Hoth Therapeutics Inc. are owned by institutional investors. XBiotech Inc.’s share owned by insiders are 37.5%. On the other hand, insiders owned about 26.59% of Hoth Therapeutics Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
XBiotech Inc. 13.76% 40.3% 121% 137.44% 90.53% 82.28%
Hoth Therapeutics Inc. -8.99% 0% 0% 0% 0% -31.18%

For the past year XBiotech Inc. has 82.28% stronger performance while Hoth Therapeutics Inc. has -31.18% weaker performance.


On 4 of the 6 factors Hoth Therapeutics Inc. beats XBiotech Inc.

XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The companyÂ’s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases. XBiotech, Inc. was founded in 2005 and is headquartered in Austin, Texas.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *